SCHEMBL6571385

SCHEMBL6571385

O=C(NN=Cc1ccc(O)c(O)c1O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
KDM4E B2RXH2 2/20 0.58
KMT2A Q03164 2/20 0.58
LMNA P02545 1/20 0.58
POLB P06746 1/20 0.58
PTBP1 P26599 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
NTRK1 P04629 1/20 0.55
SIRT1 Q96EB6 1/20 0.55
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC8 Q9BY41 1/20 0.54
HDAC6 Q9UBN7 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6747942 1.00 MAPT (0.61) MAPTKDM4EKMT2ALMNAPOLB
SCHEMBL6571625 0.89 KDM4E (0.74) MAPTKDM4EKMT2ALMNAPOLB
SCHEMBL6571628 0.89 KDM4E (0.74) MAPTKDM4EKMT2ALMNAPOLB
SCHEMBL12388078 0.84 MAPT (0.70) MAPTNTRK1HDAC3HDAC4HDAC1
SCHEMBL6751406 0.80 MAPT (0.58) MAPTKMT2APOLBNTRK1HDAC3
SCHEMBL6751404 0.80 MAPT (0.58) MAPTKMT2APOLBNTRK1HDAC3
SCHEMBL12746327 0.80 POLB (0.58) MAPTKDM4EKMT2ALMNAPOLB
SCHEMBL28429011 0.80 MAPT (0.77) MAPTSMN1; SMN2NTRK1HDAC3HDAC4
SCHEMBL19283300 0.78 MAPT (0.79) MAPTNTRK1HDAC3HDAC4HDAC1
SCHEMBL6568245 0.78 MAPT (0.74) MAPTNTRK1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO MAPT 3140/4885KDM4E 3228/4885KMT2A 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.